Latest & greatest articles for lisdexamfetamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lisdexamfetamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lisdexamfetamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lisdexamfetamine

1. Lisdexamfetamine

Lisdexamfetamine Top results for lisdexamfetamine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lisdexamfetamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical

Trip Latest and Greatest2018

2. Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. %PDF-1.5 %���� 51 0 obj > endobj 69 0 obj >/Filter/FlateDecode/ID[ ]/Index[51 36]/Info 50 0 R/Length 88/Prev 198239/Root 52 0 R/Size 87/Type/XRef/W[1 2 1]>>stream h�bbd``b`� $���" ��$�߃�� � H�F+D�q�X�@�+�M H0����A\ q������H���J��� �8 endstream endobj startxref 0 %%EOF 86 0 obj >stream h�b`````jd�2�F fa�h@�b�!���\9L� �T/p�0�3Lv���!�p�`�sҮ P

All Wales Medicines Strategy Group2015

3. Lisdexamfetamine dimesylate (Elvanse Adult®)

Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Lisdexamfetamine dimesylate (Elvanse Adult®) Penarth: All Wales Therapeutics and Toxicology (...) Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2534. 2015 Authors' conclusions Lisdexamfetamine dimesylate (Elvanse Adult®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adult; Attention Deficit Disorder with Hyperactivity

Health Technology Assessment (HTA) Database.2015

5. Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)

Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment) Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] IQWiG Record Status This is a bibliographic record of a published health technology (...) assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Lisdexamfetamindimesilat – nutzenbewertung gemäß § 35a SGB V. [Lisdexamfetamine: benefit assessment according to § 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 186. 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Attention Deficit Disorder

Health Technology Assessment (HTA) Database.2014

6. lisdexamfetamine dimesylate (Elvanse®)

lisdexamfetamine dimesylate (Elvanse®) lisdexamfetamine dimesylate (Elvanse®) lisdexamfetamine dimesylate (Elvanse®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). lisdexamfetamine dimesylate (Elvanse®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC (...) ), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 188. 2013 Authors' conclusions Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in children aged six years of age and over when response to previous methylphenidate treatment is considered clinically inadequate. Treatment must be under the supervision

Health Technology Assessment (HTA) Database.2014

7. Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD)

Lisdexamfetamine dimesylate (Elvanse) - attention deficit/hyperactivity disorder (ADHD) All Wales Medicines Strategy Group (AWMSG) - lisdexamfetamine dimesylate (Elvanse) | | Appraisal information Search and reports lisdexamfetamine dimesylate (Elvanse®) Reference No. 188 Publication date: 03/12/2013 Last review date: 01/12/2016 Appraisal information lisdexamfetamine dimesylate (Elvanse®) 30 mg capsule lisdexamfetamine dimesylate (Elvanse®) 50 mg capsule lisdexamfetamine dimesylate (Elvanse (...) ®) 70 mg capsule Company: Shire Pharmaceuticals Ltd BNF category: Central nervous system NMG meeting date: 11/09/2013 AWMSG meeting date: 16/10/2013 Submission Type: Full Submission Status: Recommended Advice No: 2813 Ministerial ratification: 02/12/2013 Current Progress Submission received NMG meeting AWMSG meeting Ministerial Ratification AWMSG advice Lisdexamfetamine dimesylate (Elvanse®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme

All Wales Medicines Strategy Group2013

12. Evaluation of the Efficacy and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Treating Children Age 6-12 with Attention Deficit Hyperactivity Disorder

Evaluation of the Efficacy and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Treating Children Age 6-12 with Attention Deficit Hyperactivity Disorder "Evaluation of the Efficacy and Tolerability of Vyvanse (Lisdexamfetami" by McKenzie Thurman < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mark Pedemonte, MD Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS (...) , PA-C Rights . Abstract Background: Lisdexamfetamine Dimesylate (LDX) is a therapeutically inactive amphetamine prodrug. Pharmacologically active d-amphetamine is released from Lisdexamfetamine following oral ingestion. It is indicated in the treatment of children ages 6-12 with Attention Deficit Hyperactivity Disorder (ADHD). The goal of LDX is to provide a one dose, extended release medication throughout the day as well as a reduced potential for abuse, overdose toxicity and drug misuse

Pacific University EBM Capstone Project2009